Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for ADHD in Smith-Magenis syndrome
NL-OMON20117Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) and Smith-Magenis syndrome (SMS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Strengths and Difficulties Questionnaire hyperactivity/inattention subscale. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)Smith-Magenis syndrome (SMS)
Beyond the preview
Go deeper on NL-OMON20117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20117.